Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. reports developments in biotechnology and precision intracellular drug delivery through its proprietary Accum® platform. Company news centers on cancer-therapy applications, including antibody-drug conjugates, radiopharmaceutical and radio-immunoconjugate programs, and other complex biologics designed for intracellular and nuclear delivery.
Recurring updates also cover scientific advisory activity, industry presentations, collaboration work such as its program with Canadian Nuclear Laboratories, partnership outreach, and capital-structure actions including private placements, warrant amendments, and restricted stock unit grants.
Defence Therapeutics (OTCQB: DTCFF) reported preclinical in vivo results for Accum-Kadcyla in HER2-positive breast cancer mouse models on November 4, 2025.
The study found ~20-fold higher anti-tumor efficacy for Accum-Kadcyla versus Kadcyla at the same dose 0.5 mg/kg, with tumor growth largely halted and a durable near-complete response in most treated mice. 100% survival and no signs of toxicity were reported during the study. Defence plans additional HER2-positive and HER2-low model testing and to advance partner discussions.
Defence Therapeutics (OTCQB: DTCFF) will present new scientific data on its Accum technology at the 16th World ADC Conference in San Diego on November 4-5, 2025.
The presentation highlights Accum's role in improving intracellular delivery and endosomal escape for antibody-drug conjugates (ADCs), aiming to enhance potency and reduce off-target toxicity. Company scientists Maxime Parisotto and Mark Lambermon will be available at the poster in the Conference Exhibition Hall, Town & Country Resort, to discuss the results and ongoing R&D.
Defence Therapeutics (OTCQB: DTCFF) will attend CPHI Worldwide 2025 in Frankfurt, Germany from October 28-30, 2025, the company stated on October 6, 2025. According to the press release, Defence plans to engage potential partners across the biopharma value chain, learn about pharmaceutical manufacturing trends, and connect with international collaborators and shareholders.
The company also invited attendees to an informal Meet & Greet on October 29, 2025 from 4:30–6:30 PM at the American May lobby bar of the Kimpton Hotel in Frankfurt and listed contact options via the CPHI partnering platform and LinkedIn for named company representatives.
Defence Therapeutics (OTCQB: DTCFF) has appointed Dr. Mark Lambermon as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience in pharmaceutical R&D, biotech innovation, and commercial manufacturing, having held key positions at AbbVie Inc. and Baxter Healthcare.
Dr. Lambermon's expertise includes leading global CMC programs, supplier oversight, and implementing GMP-compliant quality systems. He holds a PhD in Cellular Biology from the University of Basel and has completed postdoctoral fellowships at prestigious institutions. As part of his compensation, he was granted 100,000 stock options at $0.80 per share, vesting immediately with a three-year exercise period.
Defence Therapeutics (OTCQB:DTCFF) featured Dr. Amie Phinney, Director of Strategy & Business Advisor, in an interview on Money Talk Radio discussing the company's Accum® drug delivery platform. The interview highlighted how Accum® technology enhances Antibody-Drug Conjugates (ADCs) delivery by improving payload efficiency and reducing toxic side effects.
Dr. Phinney explained that Accum® provides "laser-guided precision" for cancer cell targeting, potentially enabling ADCs to transition from second-line to first-line therapy by addressing dose-limiting toxicity issues. The company's strategy includes worldwide IP protection and plans to partner with existing ADC developers while manufacturing Accum® for various therapeutic applications.
Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has appointed Dr. Amie Phinney, PhD, MBA to its Board of Directors. Dr. Phinney, who recently joined as Strategy and Business Advisor, will now expand her role to help drive governance and long-term value creation.
The company has granted Dr. Phinney 100,000 stock options, exercisable at $0.75 per share for three years, vesting immediately. This appointment strengthens Defence's leadership team as it advances its drug-delivery platform development.
Defence Therapeutics (OTCQB: DTCFF) has successfully completed a non-brokered private placement of debenture units, raising $2 million in gross proceeds. Each unit, priced at $1,000, comprises an 8.0% convertible debenture maturing September 15, 2027, and 1,666 common share purchase warrants.
The debentures are convertible into common shares at $0.60 per share, while warrants are exercisable at $0.75 per share. The company paid $160,000 in finder's fees and issued 266,667 finder's warrants. The proceeds will be used to advance Defence's science programs and for working capital.
Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has appointed Dr. Amie Phinney as Strategy & Business Advisor. Dr. Phinney brings over 20 years of experience in pharmaceutical R&D and biotech innovation, having held key positions at Abbott, AbbVie, and Solvay Pharmaceuticals.
Dr. Phinney's extensive background includes serving as Chief Scientific Officer at Lakeside Discovery and Senior Director of Partnerships at adMare BioInnovations. She holds a PhD in Biomedical Research and an MBA, with additional executive training from prestigious institutions. The appointment aims to help Defence Therapeutics capitalize on new opportunities emerging from recent scientific advances in antibody-delivered therapeutics.
Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has announced a non-brokered private placement of debenture units. The company aims to raise up to $1.2 million through the offering of units priced at $1,000 each.
Each unit comprises an 8.0% convertible debenture with a two-year maturity and 1,666 common share purchase warrants. The debentures are convertible into common shares at $0.60 per share, while warrants are exercisable at $0.75 per share for two years. Interest payments will be made annually either in shares at the conversion price or in cash at the company's discretion.
Defence Therapeutics (OTCQB: DTCFF) has announced progress in its cancer therapy programs utilizing its proprietary Accum® technology in both Antibody Drug Conjugates (ADCs) and radiopharmaceuticals. The company's Accum®-based ADCs have shown enhanced efficacy in preclinical cancer models compared to conventional ADCs.
Defence is conducting studies through the Canadian Nuclear Laboratories under the CNRI-H program, focusing on biodistribution, pharmacokinetic profiles, and therapeutic potency. The company operates primarily from its Montreal laboratory while planning U.S. expansion. The target markets show significant potential, with the global ADC market projected to reach $29.9 billion by 2034 (9.23% CAGR) and the radiopharmaceutical market expected to hit $16.87 billion by 2033 (9.9% CAGR).